文献速递慢阻肺

IL-33单抗tozorakimab治疗慢阻肺的2a期FRONTIER-4试验

A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4.
PubMed 文献 · Eur Respir J · 2025-07-14

FRONTIER-4是一项2a期随机双盲安慰剂对照研究,评估tozorakimab(抗IL-33单抗)在135例中重度慢阻肺伴慢性支气管炎患者中的疗效。主要终点(第12周支扩前FEV1变化)未达统计学显著,但支扩后FEV1显著改善,且在既往≥2次急性加重亚组中观察到更明显的疗效信号。

要点

  • 主要终点未达统计学显著:第12周支扩前FEV1组间差异24 mL(p=0.216)。
  • 支扩后FEV1显著改善:组间差异67 mL(p=0.044)。
  • 既往≥2次急性加重亚组中疗效信号更强,支扩后FEV1差异124 mL(p=0.020)。

核心结论

  • 在意向治疗人群中主要终点未达到,但tozorakimab在急性加重高风险亚组中显示出积极疗效信号。

研究设计与样本

  • FRONTIER-4(NCT04631016)为2a期随机双盲安慰剂对照研究,纳入135例中重度慢阻肺伴慢性支气管炎且接受双联或三联吸入治疗的患者。
  • 患者每4周皮下注射tozorakimab 600 mg或安慰剂,共24周;主要终点为基线至第12周支扩前FEV1变化。

主要发现

  • 意向治疗人群第12周支扩前FEV1组间最小二乘均值差(LSMD)为24 mL(80%CI -15至63 mL,p=0.216),差异无统计学意义。
  • 意向治疗人群第12周支扩后FEV1的LSMD为67 mL(80%CI 17至116 mL,p=0.044),差异有统计学意义。
  • 预设亚组(既往≥2次急性加重)第12周支扩前FEV1的LSMD为69 mL(80%CI 9至130 mL,p=0.072),支扩后FEV1的LSMD为124 mL(80%CI 47至201 mL,p=0.020)。
  • 意向治疗人群COPD复合急性加重事件风险未显著降低(HR 0.79,80%CI 0.57至1.11,p=0.186);既往≥2次急性加重亚组HR为0.61(80%CI 0.37至1.00)。
  • tozorakimab耐受性良好, former和current smokers结果相似。

关键数值与推荐

  • 主要终点:第12周支扩前FEV1变化,LSMD 24 mL(80%CI -15至63 mL,p=0.216),未达统计学显著。
  • 关键次要终点:第12周支扩后FEV1变化,LSMD 67 mL(80%CI 17至116 mL,p=0.044)。
  • 预设亚组(既往≥2次急性加重):支扩后FEV1 LSMD 124 mL(80%CI 47至201 mL,p=0.020);复合急性加重事件HR 0.61(80%CI 0.37至1.00)。

临床怎么用

  • 目前证据尚不支持在全体中重度慢阻肺伴慢性支气管炎患者中常规使用tozorakimab。
  • 对于既往频繁急性加重(≥2次/年)且接受双联或三联吸入治疗的患者,tozorakimab可能带来肺功能及急性加重方面的获益趋势。

局限性

  • 本研究为2a期探索性试验,样本量较小(意向治疗人群135例),主要终点未达到统计学显著。
  • 亚组分析为预设但样本量有限,疗效信号需在更大规模3期试验中验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Interleukin-33 may have a role in COPD pathobiology. FRONTIER-4 (NCT04631016) investigated tozorakimab (an anti-interleukin-33 monoclonal antibody) in patients with moderate-to-severe COPD with chronic bronchitis receiving dual or triple inhaled therapy. METHODS: FRONTIER-4 was a phase 2a, randomised, double-blind, placebo-controlled study. Patients received tozorakimab 600 mg or placebo subcutaneously every 4 weeks for 24 weeks. The primary end‑point was change in pre-bronchodilator forced expiratory volume in 1 s (FEV1) from baseline to week 12. Secondary outcomes included post-bronchodilator FEV1, time-to-first COPD composite exacerbation event and safety. RESULTS: The intent-to-treat population included 135 patients (tozorakimab, n=67; placebo, n=68). At week 12 in the intent-to-treat population, tozorakimab showed a greater increase, although nonsignificant, from baseline in pre-bronchodilator FEV1 (least-squares mean difference (LSMD) 24 mL, 80% confidence interval (CI) -15-63 mL, p=0.216) and a significantly greater increase in post-bronchodilator FEV1 (LSMD 67 mL, 80% CI 17-116 mL, p=0.044) when compared with placebo. At week 12 in a prespecified subgroup of patients with at least two prior exacerbations, tozorakimab also showed improvements versus placebo in change from baseline in pre-bronchodilator FEV1 (LSMD 69 mL, 80% CI 9-130 mL, p=0.072) and post-bronchodilator FEV1 (LSMD 124 mL, 80% CI 47-201 mL, p=0.020). Tozorakimab did not significantly reduce the risk of COPD composite exacerbation events (hazard ratio 0.79, 80% CI 0.57-1.11, p=0.186) in the intent-to-treat population, although there were greater effects in patients with at least two prior exacerbations (hazard ratio 0.61, 80% CI 0.37-1.00). Results were similar in former and current smokers. Tozorakimab was well tolerated. CONCLUSION: Although the primary end-point was not met in the intent-to-treat population, tozorakimab showed positive efficacy signals versus placebo in a subgroup of patients with COPD with a high risk of exacerbations.

来源:Eur Respir J,查看原文。版权归原作者所有。

引用

  1. Singh, Guller, Reid, et al. A phase 2a trial of the IL-33 monoclonal antibody tozorakimab in patients with COPD: FRONTIER-4. Eur Respir J. 2025. PMID: 40154559. doi:10.1183/13993003.02231-2024

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。